Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04082416
Recruitment Status : Recruiting
First Posted : September 9, 2019
Last Update Posted : December 3, 2019
Sponsor:
Information provided by (Responsible Party):
RemeGen

Brief Summary:
The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Biological: Placebo plus standard therapy Biological: RC18 160 mg plus standard therapy Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 318 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-exploring Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).
Actual Study Start Date : October 10, 2019
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Arm Intervention/treatment
Experimental: RC18 160mg
Patients received the test group RC18 160mg weekly administered subcutaneously for 52 times.
Biological: RC18 160 mg plus standard therapy
Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
Other Name: Standard therapy

Placebo Comparator: Placebo
Patients received the test group Placebo weekly administered subcutaneously for 52 times.
Biological: Placebo plus standard therapy

Standard therapy comprises any of the following (alone or in combination):

corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )

Other Name: Standard therapy




Primary Outcome Measures :
  1. SLE Responder Index (SRI) Response Rate [ Time Frame: Week 52 ]
    At Week 52 the percent of subjects with ≥ 4 point reduction from baseline in SELENA-SLEDAI score and increasing no more than 0.3 points in PGA and no new BILAG A organ domain score or 1 new BILAG B organ domain scores compared with baseline at the time of assessment


Secondary Outcome Measures :
  1. Percent of subjects with ≥ 4 point reduction from baseline in SELENA-SLEDAI score [ Time Frame: Week 52 ]
  2. Mean Change From Baseline in Physician's global assessment(PGA) [ Time Frame: Week 52 ]
    Physician's global assessment, PGA.The measurement tool is Visual Analogue Scale/Score(VAS).The doctor assesses participant's disease activity on a VAS of 0-100 mm on the questionnaire form.The higher values represent a worse outcome.There are not combined subscales.

  3. Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline or ≤ 7.5 mg/Day,During Weeks 44 Through 52. [ Time Frame: Week 44 through 52 ]
  4. Mean Change From Baseline in Serological Examination Index [ Time Frame: week 52 ]
  5. The flare time after randomization [ Time Frame: 52 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Active SLE disease#and at least according with 4 of the 11 items of the American College of Rheumatology (ACR) criteria 1997.
  • Age & Gender: Male or female between 18 and 65 years of age inclusive#and the sex ratio is not limited
  • Signed informed consent form#willing or able to participate in all required study evaluations and procedures.
  • SELENA-SLEDAI(Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index) score ≥ 8 during the screening period.and if there is Hypo-complement or the Anti-dsDNA score, SELENA-SLEDAI disease activity score should be at least 6 at screening .
  • Autoantibody-positive
  • on a stable SLE treatment regimen for at least 30 days prior to Day 1, which consisted of any of the following (alone or in combination): cortical hormone,anti-malarials,non-steroidal anti inflammatory drugs (NSAIDs),or any immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate

Exclusion Criteria:

  • kidney disease :Severe lupus nephritis 8 weeks prior to randomization (designed as:Urine protein>6g/24h or serum creatinine ( SCr>2.5mg/dL or 221umol/L ) or needing for hemodialysis or receipting high dose cortical hormone ≥14 days( metacortandracin>100mg/d or equivalent)
  • Central nervous system disease caused by SLE or non SLE 8 weeks prior to randomization (including epilepsy、 mental disease、organic encephalopathy syndrome、cerebrovascular accident, encephalitis, central nervous system vasculitis;
  • there are serious heart, liver, kidney and other important organs and blood, endocrine system diseases and medical history;

Evaluation criteria for severity :

  1. Alanine aminotransferase#ALT#or aspartate aminotransferase (AST) ≥2 upper limit of normal (ULN);
  2. Creatinine Clearance (Ccr)<30ml/min;
  3. White Blood Cell Count(WBCs)<2.5x 10(9)/L;
  4. hemoglobin<85g/L;
  5. Platelets<50x 10(9)/L.

    • Have a historically active hepatitis or active hepatitis or medical history,hepatitis B :Patients with positive HBsAg are excluded.;Hepatitis C: Patients with hepatitis C antibody positive are excluded;
    • Immune deficiency, uncontrolled severe infection and patients with active or recurrent peptic ulcer;
    • Pregnant , lactating women and men or women who have birth plans in the past 12 months ;
    • Have a history of allergic reaction to human biological medicines.
    • Receipt of live vaccine within 1 month;
    • Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the elderly).
    • Have received treatment with B cell targeted therapy such as Rituximab or Epratuzumab etc.
    • Receipt of anti-tumor necrosis factor#interleukin receptor antagonist#
    • Receipt of IV immunoglobulin(IVIG),prednisone>100mg/d more than 14 days or plasma exchange;
    • There are active infections (such as herpes zoster, human immunodeficiency virus (HIV) virus infection, active tuberculosis, etc.) during the screening period;
    • Patients have depression or the significant suicide ideation;
    • Interleukin(IL)-2, thalidomide, Tripterygium wilfordii and traditional Chinese medicine preparation containing Tripterygium Wilfordii were used within 28 days before randomization
    • Investigator considers candidates not appropriating for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04082416


Contacts
Layout table for location contacts
Contact: Binghua Xiao 86-010-58076833 Binghua.xiao@remegen.cn

Locations
Layout table for location information
China, Shandong
Remegen,ltd. Recruiting
Yantai, Shandong, China
Contact: Wenxiang Wang, M.D.    86-010-58075563    wenxiang.wang@remegen.cn   
Sponsors and Collaborators
RemeGen
Investigators
Layout table for investigator information
Principal Investigator: Fengchun Zhang, M.D. Peking Union Medical College Hospital

Layout table for additonal information
Responsible Party: RemeGen
ClinicalTrials.gov Identifier: NCT04082416    
Other Study ID Numbers: 18C010
First Posted: September 9, 2019    Key Record Dates
Last Update Posted: December 3, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases